Brio Pharmaceuticals, Inc.

Form 483 issued January 24, 2020 · Houston, Texas

Inspection
Jan 15 – Jan 24, 2020
Investigator
Camerson E. Moore
Observations
1
Pages
2
FEI number
1628196

In short: On January 24, 2020, FDA issued a Form 483 with 1 observation to Brio Pharmaceuticals, Inc. in Houston, Texas (FEI 1628196) after an inspection that ran Jan 15 – Jan 24, 2020. The investigator was Camerson E. Moore. Most observations concern quality system; the most-cited regulation is 21 CFR 211.22 (responsibilities of quality control unit).

At a glance

1 of 1 observations on this 483 concern quality system.

Quality system1

Most cited: 21 CFR 211.22 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    The responsibilities and procedures applicable to the quality control unit…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Brio Pharmaceuticals, Inc.?

FDA listed 1 observation on this Form 483, mostly about quality system. The most-cited regulation is 21 CFR 211.22 (responsibilities of quality control unit). The opening words of each observation are shown on this page.

Who inspected Brio Pharmaceuticals, Inc.?

Camerson E. Moore is named on this Form 483, for the inspection of Jan 15 – Jan 24, 2020. Each investigator has a profile showing what they cite most.

When was Brio Pharmaceuticals, Inc. inspected by FDA?

The inspection ran Jan 15 – Jan 24, 2020, and the Form 483 is dated January 24, 2020.

How do I get the full Form 483 for Brio Pharmaceuticals, Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free